SCHEMBL894337

SCHEMBL894337

O=C(O)c1ccc(NS(=O)(=O)CCc2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.56
LMNA P02545 1/20 0.53
ACLY P53396 1/20 0.52
IDO1 P14902 1/20 0.51
MMP8 P22894 2/20 0.50
MMP12 P39900 2/20 0.50
MMP13 P45452 2/20 0.50
MMP1 P03956 1/20 0.50
MMP7 P09237 1/20 0.50
MCL1 Q07820 1/20 0.49
BCL2A1 Q16548 1/20 0.49
KMT2A Q03164 3/20 0.49
PTGES2 Q9H7Z7 1/20 0.49
TSHR P16473 2/20 0.47
HSD17B10 Q99714 1/20 0.47
ADRB2 P07550 2/20 0.47
ADRB1 P08588 2/20 0.47
NR3C1 P04150 1/20 0.47
ADRB3 P13945 1/20 0.46
CA12 O43570 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9689747 0.88 HPGD (0.74) HPGDLMNAACLYIDO1MMP8
SCHEMBL9689773 0.85 HPGD (0.51) HPGDLMNAACLYIDO1MMP8
SCHEMBL3560317 0.85 HPGD (0.69) HPGDLMNAMMP8MMP13MMP1
SCHEMBL15622087 0.85 IDO1 (0.68) HPGDACLYIDO1MMP8MMP12
SCHEMBL1650346 0.84 HPGD (0.77) HPGDLMNAACLYMMP8MMP13
SCHEMBL10056646 0.84 POLB (0.52) ACLYIDO1MCL1BCL2A1KMT2A
SCHEMBL23275661 0.81 PTGES2 (0.57) HPGDACLYIDO1MMP8MMP12
SCHEMBL28791142 0.80 HPGD (0.50) HPGDLMNAKMT2ATSHRCA12
SCHEMBL11111941 0.80 L3MBTL1 (0.63) LMNAIDO1MMP8MMP12MMP13
SCHEMBL3558724 0.80 LMNA (0.56) HPGDLMNAKMT2ACA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102395270-B Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same FASGEN INC 2014-11-12 CN disclosed
US-20120083471-A1 Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same FAS SECURED CREDITORS HOLDCO, LLC 2012-04-05 US disclosed
US-20120083471-A1 Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same FAS SECURED CREDITORS HOLDCO, LLC 2012-04-05 US disclosed
CN-102395270-A Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same FASGEN INC 2012-03-28 CN disclosed
EP-2303013-A1 NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME Fasgen, Inc. (US) 2011-04-06 EP disclosed
WO-2010005922-A1 NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME FASGEN, INC. (US) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083471-A1 Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same LCAT, DGAT2, SOAT2 HPGD 1419/4885LMNA 4258/4885ACLY 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.